BRISTOL-MYERS SQUIBB COMPANY |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 44.85 USD | +0.34% |
|
-8.34% | -12.59% |
| 26/04 | S&P 500 Q1 earnings estimated growth improves; stocks up for week | RE |
| 26/04 | Leerink Partners Cuts Price Target on Bristol-Myers Squibb to $47 From $51 | MT |
ETFs positioned on Bristol-Myers Squibb Company
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 12.97% | 215 M€ | +10.68% | - | |
| 4.99% | 2 M€ | -.--% | ||
| 4.01% | 18 M€ | +3.79% | - | |
| 2.63% | 23 M€ | +9.02% | - | |
| 2.37% | 2 M€ | -25.75% | ||
| 2.29% | 32 M€ | -0.28% | - | |
| 2.08% | 9 M€ | -.--% | - | |
| 1.90% | 16 M€ | -3.37% | ||
| 1.85% | 2 M€ | +6.77% | ||
| 1.43% | 5 M€ | -72.95% | - | |
| 1.42% | 9 M€ | -4.31% | - | |
| 1.37% | 26 M€ | +16.85% | - | |
| 1.26% | 846 M€ | +2.60% | ||
| 1.00% | 96 M€ | -1.45% | ||
| 0.99% | 10 M€ | +5.96% | ||
| 0.83% | 105 M€ | +6.17% | ||
| 0.82% | 8 M€ | +2.44% | ||
| 0.80% | 2,510 M€ | +12.00% | ||
| 0.78% | 3 M€ | +15.16% | - | |
| 0.78% | 13 M€ | -.--% | - |
Bristol-Myers Squibb Company est spécialisé dans le développement, la fabrication et la commercialisation de produits pharmaceutiques. Les produits sont destinés au traitement des cancers, des maladies cardio-vasculaires, de l'hépatite, des maladies immunitaires et des désordres psychiatriques.
The United States account for 70.1% of net sales.
Sector
Pharmaceuticals
Calendar
07/05/2024
- Annual General Meeting
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
B
Sell
Buy
Mean consensus
HOLD
Number of Analysts
27
Last Close Price
44.85
USD
Average target price
54.02
USD
Spread / Average Target
+20.45%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -12.59% | 90.92B | |
| +25.83% | 661B | |
| +27.00% | 566B | |
| -6.76% | 352B | |
| +20.34% | 332B | |
| +3.00% | 283B | |
| +13.09% | 231B | |
| +5.46% | 200B | |
| -9.61% | 195B | |
| -6.26% | 145B |
- Stock Market
- Equities
- BMY Stock
- Funds and ETFs Bristol-Myers Squibb Company
